In one paragraphArticle in Journal of xenobiotics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
16 authors.
Wasima Oualla-BachiriCentro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, 28029 Madrid, Spain.ORCID 0000-0002-9760-0883 Ana Lago-SampedroCentro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, 28029 Madrid, Spain.
Eva García-EscobarCentro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, 28029 Madrid, Spain.ORCID 0000-0002-0134-3473 Cristina Maldonado-AraqueCentro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, 28029 Madrid, Spain.ORCID 0000-0002-3452-3489 Viyey Doulatram-GamgaramCentro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, 28029 Madrid, Spain.ORCID 0000-0002-0178-0040 Marta García-VivancoDivisión De Contaminación Atmosférica, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), 28040 Madrid, Spain.
Fernando Martín-LlorenteDivisión De Contaminación Atmosférica, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), 28040 Madrid, Spain.ORCID 0000-0002-4654-9272 Juan Luis GarridoDivisión De Contaminación Atmosférica, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), 28040 Madrid, Spain.ORCID 0000-0002-9417-1905 Elías DelgadoCentro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto De Salud Carlos III, 28029 Madrid, Spain.ORCID 0000-0001-6114-9712 Felipe J ChavesCentro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, 28029 Madrid, Spain.ORCID 0000-0001-8009-3689 Luis CastañoCentro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, 28029 Madrid, Spain.
Alfonso Calle-PascualCentro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, 28029 Madrid, Spain.ORCID 0000-0002-3628-9323 Josep Franch-NadalCentro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, 28029 Madrid, Spain.ORCID 0000-0002-5175-1555 Gabriel OlveiraCentro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, 28029 Madrid, Spain.ORCID 0000-0002-7646-2899 Sergio ValdésCentro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, 28029 Madrid, Spain.
Gemma Rojo-MartínezCentro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, 28029 Madrid, Spain.ORCID 0000-0003-2179-2134 Funding
Consejería de Salud, Junta de Andalucía, Spain C-0060-2012Instituto de Salud Carlos III (ISCIII), Spain FI21/0040Instituto de Salud Carlos III (ISCIII), Spain PI17/02136Instituto de Salud Carlos III (ISCIII), Spain PI20/01322Instituto de Salud Carlos III (ISCIII), Spain PI23/00347
6 · The paper itselfAbstract
It is well known that environmental factors influence the risk of type 2 diabetes mellitus (T2DM). Several studies have linked the xenobiotics present in tobacco or air pollutants to T2DM development, although the underlying mechanisms remain unclear. Surfactant protein D (SP-D), an immune component released into the bloodstream after lung injury, has been associated with metabolic diseases. The aim of this study was to investigate whether SP-D mediates the effects of smoking or air pollution exposure on T2DM risk in the Spanish adult population. Socio-demographic, lifestyle (including smoking status) and clinical data from 2155 participants from the Di@bet.es cohort were analyzed. Annual concentrations of PM
Indexed as
air pollutantsbiomarkersincidencemediationsmokingSP-Dtype 2 diabetes mellitusxenobiotics
Identifiers
PMID41283421
PMCPMC12641695
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390